

OAB, IC and Pelvic Pain, Prolapse Poster Session

MODERATED

Poster# 77

EFFICACY OF A SUPERSATURATED CALCIUM PHOSPHATE ORAL RINSE (CAPHOSOL) IN THE TREATMENT OF XEROSTOMIA SECONDARY TO ANTIMUSCARINIC TREATMENT FOR THE BLADDER

Katherine Klos, MD¹ and Tiffany Sotelo, MD²

¹George Washington University, Washington, DC; ²George Washington University, Washington, DC

(Presented by: Katherine Klos)

Poster# 78

BASELINE PREDICTORS OF PATIENT REPORTED LACK OF EFFICACY (LOE) TO ANTIMUSCARINICS IN OVERACTIVE BLADDER SYNDROME (OAB): A MULTIVARIATE ANALYSIS

David Staskin, MD¹, Michael Oefelein, MD, FACS² and Ray Rackley, MD³

¹Tufts University, Boston, MA; ²Allergan LLC, Irvine, CA; ³Cleveland Clinic Foundation, OH

(Presented by: David Staskin)

Poster# 79

MENTAL DISTRESS PREDICTS PAIN SEVERITY, PHYSICAL IMPAIRMENT IN INTERSTITIAL CYSTITIS AND CHRONIC PELVIC PAIN

Chad Baxter, MD¹, Roger Bolus, PhD², Una Lee, MD³ Emeran Mayer¹, Deborah Ackerman, PhD⁴, and Larissa Rodriguez, MD³

¹UCLA Urology, Los Angeles, CA; ²Research Solutions Group; ³UCLA Urology; ⁴UCLA School of Public Health

(Presented by: Chad Baxter)

Poster# 80

THE OVERACTIVE BLADDER SYNDROME (OAB) AND OBESITY: EVIDENCE OF ANTIMUSCARINIC EFFICACY REGARDLESS OF BODY MASS INDEX AT BASELINE

Michael Chancellor, MD¹, Michael Oefelein, MD, FACS² and Sandip Vasavada, MD³

¹William Beaumont Hospital; ²Allergan LLC, Irvine, CA; ³Cleveland Clinic Foundation, OH

(Presented by: Michael Chancellor)

Poster# 81

PATIENTS' EXPERIENCE WITH DARIFENACIN: RESULTS OF A COMMUNITY-BASED SURVEY IN OVERACTIVE BLADDER PATIENTS

Diane Newman¹ and L. Green²

¹University of Pennsylvania, Philadelphia PA; ²Virginia Women's Center, Richmond, VA

(Presented by: Diane Newman)

Poster# 82

A RANDOMIZED, PLACEBO CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECTS OF TOLTERODINE ON URODYNAMIC PARAMETERS IN PATIENTS WITH OVERACTIVE BLADDER

Tara Frenkl¹, Radha A. Railkar¹, Neal Shore², James Bailen³, Suzette E. Sutherland⁴, Joanne Burke¹, Boyd B. Scott¹, Marcella Ruddy¹ and Chan Beals¹

¹Merck Research Laboratories, Whitehouse Station, NJ; ²Atlantic Urology Clinics, Myrtle Beach, SC; ³Metropolitan Urology, Jeffersonville, IN; ⁴Metropolitan Urologic Specialists, Plymouth, MN

(Presented by: Tara Frenkl)

Poster# 83

CHRONIC PELVIC PAIN PATIENTS WITH NEUROPATHIC SYMPTOMS DEMONSTRATE POORER MENTAL HEALTH STATUS

Sandeep S. Saluja, BS, Arvin George, MD¹, Mostafa Sadek, MD¹, Jennifer Fariello, MSN, CRNP², Kristene Whitmore, MD², Salim Wehbe, MD² and Robert Moldwin, MD¹

¹The Arthur Smith Institute for Urology, New Hyde Park, NY; ²Pelvic and Sexual Health Institute, Philadelphia, PA

(Presented by: Sandeep S. Saluja)

Poster# 84

LONG-TERM TOLERABILITY AND EFFICACY OF PENTOSAN POLYSULPHATE SODIUM IN THE TREATMENT OF PAINFUL BLADDER SYNDROME/ INTERSTITIAL CYSTITIS (PBS/IC)

Ali AL-Zahrani and Jerzy Gajewski

(Presented by: Ali AL-Zahrani)

Poster# 85

EFFECTS OF OXYBUTYNIN TOPICAL GEL ON GASTRIC EMPTYING

Naomi Dahl, PharmD¹, Marilyn McIlwain, BS² and Weining Volinn, MS³

¹Watson Laboratories, Inc., Morristown, NJ; ²Watson Laboratories, Morristown, NJ; ³Watson Laboratories, Salt Lake City, UT

(Presented by: Naomi Dahl)

Poster# 86

EARLY LIFETIME TRAUMA IMPACTS SYMPTOM SEVERITY OF INTERSTITIAL CYSTITIS AND CHRONIC PELVIC PAIN

Chad Baxter, MD¹, Roger Bolus, PhD², Deborah Ackerman, PhD³ Emeran Mayer¹, and Larissa Rodriguez, MD⁴

¹UCLA Urology, Los Angeles, CA; ²Research Solutions Group; ³UCLA School of Public Health; ⁴UCLA Urology

(Presented by: Chad Baxter)

NON-MODERATED

Poster# 87

A ONCE DAILY (QD) EXTENDED RELEASE (ER) ANTIMUSCARINIC REDUCES NOCTURNAL AS WELL AS DAYTIME TOILET VOIDS IN OVERACTIVE BLADDER SYNDROME (OAB)

David Ginsberg, MD¹ and Michael Oefelein, MD, FACS²

¹USC, Keck; ²Allergan LLC, Irvine, CA

(Presented by: David Ginsberg)

Poster# 88

EFFECT OF OXYBUTYNIN CHLORIDE TOPICAL GEL ON QUALITY OF LIFE IN WOMEN WITH OVERACTIVE BLADDER

Diane Newman¹, Delbert C. Rudy², Roger R. Dmochowski³, Kim E. Caramelli⁴, Heather Thomas⁴, Gary Hoel⁴ and Philip M. Hanno⁵

¹University of Pennsylvania Medical Center, Division of Urology, Penn Center for Continence and Pelvic Health; ²Urology Associates of North Texas, Arlington, TX; ³Vanderbilt Continence Center, Vanderbilt University School of Medicine, Nashville, TN; ⁴Watson Laboratories, Inc., Salt Lake City, UT; ⁵Division of Urology, Hospital of the University of Pennsylvania, Philadelphia, PA

(Presented by: Diane Newman)

Poster# 89

LINEAR CORRELATION AND REGRESSION BETWEEN SEVERITY OF URGE SENSATION AND VOIDED VOLUME IN PATIENTS WITH OAB: A DIFFERENT APPROACH TO UNDERSTAND URGENCY

Zhonghong Guan, MD, PhD¹, Miriam Harel, MD², Jeffrey P. Weiss, MD³, Joseph Wang, MS¹ and Jerry G. Blaivas, MD³

¹Pfizer Inc, New York, NY; ²SUNY Downstate Medical School, Brooklyn, NY; ³SUNY Downstate Medical School, Brooklyn, NY

(Presented by: Miriam Harel)

Poster# 90

DO PATIENTS UNDERSTAND LOWER URINARY TRACT SYMPTOM TERMINOLOGY?

Nadya Cinman, MD¹, Amin Herati, MS^{2,3} and Robert Moldwin MD^{2,3}

¹North Shore/Long Island Jewish; ²Smith Institute for Urology; ³North Shore/Long Island Jewish Health System (New Hyde Park, NY)

(Presented by: Nadya Cinman)

Poster# 91

INTRAVESICAL BUPIVACAINE FOR LIDOCAINE-REFRACTORY PATIENTS WITH PAINFUL BLADDER SYNDROME/INTERSTITIAL CYSTITIS

Renee Quillin, MD, Gwen Hooper, ARNP and Deborah Erickson, MD

University of Kentucky, Lexington, KY

(Presented by: Renee Quillin)

Poster# 92

THE EFFICACY OF VAGINAL DIAZEPAM USE FOR PELVIC FLOOR DYSFUNCTION PAIN, INTERSTITIAL CYSTITIS, AND/OR VULVAR PAIN: PRELIMINARY DATA

Donna J. Carrico, NP, MS, Frank Burks, MD and Kenneth M. Peters, MD

Beaumont, Royal Oak, MI

(Presented by: Donna J. Carrico)

Poster# 93

SLEEP DISRUPTION IN WOMEN WITH OVERACTIVE BLADDER (OAB): CHARACTERISTICS AND IMPACT

Diane Newman¹ and Patricia Koochaki²

¹University of Pennsylvania, Philadelphia, PA; ²Procter & Gamble Pharmaceuticals, Inc., Mason, OH

(Presented by: Diane Newman)

Poster# 94

MINIMUM IMPORTANT DIFFERENCE FOR VALIDATED INSTRUMENTS IN WOMEN WITH URGE INCONTINENCE

Keisha Dyer, MD, MPH¹, Linda Brubaker, MD, MS², Toby Chai, MD³, Emily Lukacz, MD, MAS⁴, Alayne Markland, DO, MSc⁵, Ingrid Nygaard, MD⁶, David Rahn, MD⁷, Anne Stoddard, ScD⁸ and Yan Xu, MS, for the Urinary Incontinence Treatment Network (UITN)

¹University of California-San Diego, La Jolla CA; ²Loyola University, Chicago, IL; ³University of Maryland, Baltimore, MD; ⁴University of California-San Diego, La Jolla, CA; ⁵University of Alabama, Birmingham, AL; ⁶University of Utah, Salt Lake, UT; ⁷University of Texas, Southwestern, Dallas, TX; ⁸New England Research Institutes, Watertown, MA; New England Research Institute, Watertown, MA

(Presented by: Keisha Dyer)

Poster# 95

RELIABILITY AND VALIDITY OF THE OVERACTIVE BLADDER SYMPTOM SCORE IN SPANISH (OABSS-S)

Aaron Weinberg, BS, Gabriel Brandeis, MD¹, Jeffery Weiss, MD², John Bruyere, BS¹, Matthew Rutman, MD³ and Jerry Blaivas, MD⁴

¹Boston University Medical Center, Boston MA; ²Downstate Medical Center, Brooklyn NY; ³Columbia Medical Center, New York, NY; ⁴Cornell Medical Center, New York, NY

(Presented by: Aaron Weinberg)

Poster# 96

THE SAFETY OF ONCE-DAILY EXTENDED RELEASE ANTIMUSCARINIC THERAPY IN MEN WITH OVERACTIVE BLADDER SYNDROME

Scott Macdiarmid, MD, FRCPSC¹, David Sussman, MD² and Michael Oefelein, MD³

¹Greensboro, NC; ²Sewell, NJ; ³Allergan LLC, Irvine, CA

(Presented by: Scott Macdiarmid)

Poster# 97

FUNCTIONAL BLADDER CAPACITY AS AN OBJECTIVE MEASURE OF RESPONSE TO INTRAVESICAL DIMETHYL SULFOXIDE FOR THE TREATMENT OF NEWLY DIAGNOSED INTERSTITIAL CYSTITIS

Adam Gafni-Kane, MD¹, Hongyan, DU MS², Aimee Nguyen, MD¹, Manhan, Vu DO¹, Roger P. Goldberg, MD¹, Peter K. Sand, MD¹ and Sylvia Botros, MD¹

¹Evanston Continence Center, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, Chicago, IL; ²Center on Outcomes Research and Education, NorthShore University HealthSystem, Chicago, IL

(Presented by: Adam Gafni-Kane)

Poster# 98

NOCTURIA: WHY DO PEOPLE VOID AT NIGHT?

Jerry G. Blaivas, MD¹, Michael Amirian, BS², Jeffrey P. Weiss, MD³, Georgia Panagopoulos, PhD⁴, Lorraine Liang, BS³ and Stanislav Belotserkovskiy

¹Weill Medical College of Cornell University, New York, NY; ²SUNY Downstate Medical School, Brooklyn, NY; ³SUNY Downstate Medical School, Brooklyn, NY; ⁴Lenox Hill Hospital, New York, NY

(Presented by: Jeffrey P. Weiss)

Poster# 99

EFFECT OF FLEXIBLE DOSE ESCALATION IN A PLACEBO-CONTROLLED CLINICAL TRIAL OF FESOTERODINE

David R. Staskin, MD¹, Jon D. Morrow, MD, CM², Vik Khullar, MD³, Zhonghong Guan, MD, PhD² and Roger Dmochowski, MD⁴

¹Tufts University School of Medicine, Caritas-St. Elizabeth's Medical Center; ²Pfizer Inc, New York, NY; ³St. Mary's Hospital, Imperial College, London, UK; ⁴Vanderbilt University Medical Center, Nashville, TN

(Presented by: David R. Staskin)

Poster# 100

FAVORABLE ROLE OF TRIGONE FULGURATION IN THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS

Mierzwiak Jesse, MD, Sunshine Murray, MD and Philippe Zimmern, MD

UT Southwestern Medical Center, Dallas, TX

(Presented by: Mierzwiak Jesse)

Poster# 101

TRENDS IN FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY EXPOSURE DURING UROLOGY RESIDENCY

Farzeen Firoozi, MD, Howard B. Goldman, MD, Courtenay Moore, MD, Raymond Rackley, MD and Sandip Vasavada, MD

Cleveland Clinic-Glickman Urological and Kidney Institute, Cleveland, OH

(Presented by: Farzeen Firoozi)

Poster# 102

PURELY TRANSVAGINAL TECHNIQUE AND MANAGEMENT OF ALL FORMS OF MESH-RELATED COMPLICATIONS FROM COMMERCIAL PROPLAPSE KITS

Farzeen Firoozi, MD, Michael S. Ingber, MD, Charuspong Dissaranan, MD, Courtenay Moore, MD, Raymond Rackley, MD, Sandip Vasavada, MD and Howard B. Goldman, MD

Cleveland Clinic-Glickman Urological and Kidney Institute, Cleveland, OH

(Presented by: Farzeen Firoozi)

Poster# 103 – WITHDRAWN

Poster# 104

SHORT TERM SAFETY OUTCOMES OF CYSTOCELE REPAIR USING THE PERIGEE® POLYPROPYLENE MESH KIT.

Matthew McIntyre, MD¹, Bret Lebed, MD², Walker Nichols, BS¹ and Eric Rovner, MD¹

¹MUSC, Charleston, SC; ²Temple University, Philadelphia, PA

(Presented by: Matthew McIntyre)